Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Titel:
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Auteur:
Zielinski, Christoph Láng, István Inbar, Moshe Kahán, Zsuzsanna Greil, Richard Beslija, Semir Stemmer, Salomon M Zvirbule, Zanete Steger, Günther G Melichar, Bohuslav Pienkowski, Tadeusz Sirbu, Daniela Petruzelka, Luboš Eniu, Alexandru Nisenbaum, Bella Dank, Magdalena Anghel, Rodica Messinger, Diethelm Brodowicz, Thomas